EQT life science
EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EQT life science Information
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Acquirer
Geographic Data
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,837,703Website Global Rank
2,148Website Monthly Traffic
Twitter Followers
Description
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2014 | Affimed | Series E | 0 |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 5/2020 | Arvelle Therapeutics | Series A | 0 |
| 9/2016 | Immunic Therapeutics | Series A | 19.6M |
| 8/2007 | FlowCardia | Series C | 0 |
| 11/2011 | Harvest Automation | Series B | 7.9M |
| 11/2003 | Affectis Pharmaceuticals | Series A | - |
| 8/2007 | Isto Technologies | Series E | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 4/2000 | NewBiotics | Venture Round | 6.3M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 10/2015 | Luxendo | Series A | 0 |
| 5/2011 | Cobalt Technologies | Series D | 0 |
| 9/2019 | Pharvaris | Series B | 66M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 1/2009 | BMEYE | Series A | - |
| 6/2009 | Pronota | Series B | 7.4M |
| 1/2011 | Nexstim | Venture Round | 0 |
| 5/2019 | DNA Script | Series B | 38.5M |
| 3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
| 7/2020 | Cybin | Series B | 0 |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 4/2004 | NewBiotics | Series E | 4.6M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 11/2017 | Xeltis | Series C | 53M |
| 5/2008 | Asoyia | Venture Round | 4M |
| 2/2022 | Perfuze | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 8/2021 | Visus Therapeutics | Equity | 20M |
| 6/2020 | OneProjects | Series A | 12.4M |
| 1/2010 | Harvest Automation | Series A | 4M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 1/2007 | 4-Antibody AG | Series A | 18.4M |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 4/2005 | DNage | Series A | 1.9M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 4/2006 | Pronota | Series A | 7.8M |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 2/2007 | Prosensa | Series A | 18M |
| 9/2010 | Harvest Automation | Series A | 1.3M |
| 10/2013 | Harvest Automation | Series C | 11.8M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2017 | Simplify Medical | Series B | 21M |
| 2/2018 | Simplify Medical | Series B | 23M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2009 | Kreatech Diagnostics | Venture Round | 0 |
| 10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
| 9/2007 | Nexstim | Venture Round | 10.9M |
| 4/2016 | Onward | Series A | 29.5M |
| 10/1999 | Devgen | Series B | 24.7M |
| 1/2012 | Pronota | Series C | 4.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 2/2009 | ActoGeniX | Private Equity Round | 17.4M |
| 2/2007 | ActoGeniX | Venture Round | 26.1M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 7/2001 | NewBiotics | Series C | 0 |
| 9/2016 | Vivasure Medical | Series C | 18.3M |
| 7/2020 | DNA Script | Series B | 50M |
| 12/2006 | BMEYE | Series A | - |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 7/2003 | PamGene | Series B | 11.3M |
| 8/2006 | Pronota | Series A | 10.6M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 12/2018 | XyloCor Therapeutics | Series A | 17M |
| 11/2014 | Curetis | Series B | 0 |
| 6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 10/2021 | DNA Script | Series C | 0 |
| 4/2007 | Affimed | Series B | 32M |
| 8/2007 | BioProcessors | Series C | 10M |
| 8/2016 | Rotation Medical | Series B | 12M |
| 10/2012 | Affimed | Series D | 20.1M |
| 7/2014 | Rotation Medical | Series B | 27.2M |
| 7/2009 | Pasteuria Bioscience | Series B | 0 |
| 1/2021 | Neurent Medical | Series B | 0 |
| 12/2009 | Curetis | Series A | 27.9M |
| 2/2019 | Arvelle Therapeutics | Series A | 0 |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 12/2000 | PamGene | Series A | 6.2M |
| 6/2015 | Neuravi | Series B | 21.5M |
| 1/2012 | Prosensa | Venture Round | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 10/2021 | OneProjects | Series A | 8M |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 5/2023 | VarmX | Series B | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 7/2021 | Xilis | Series A | 0 |
| 7/2020 | ViCentra | Venture Round | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 1/2017 | Binx Health | Series D | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 10/2013 | Merus | Series B | 42.2M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 10/2008 | Cobalt Technologies | Series C | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 9/2018 | Endotronix | Series D | 0 |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 8/2021 | T-knife | Series B | 110M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 7/2014 | Mint Solutions | Series A | 6M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 8/2016 | Mint Solutions | Series B | 5.6M |
| 4/2014 | Binx Health | Series B | 0 |
| 4/2021 | Onward | Venture Round | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 7/2020 | VarmX | Series B | 36.3M |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 4/2023 | Evommune | Series B | 50M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
| 1/2010 | Kreatech Diagnostics | Series B | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 6/2011 | Mendor | Series B | 11.7M |
| 1/2016 | ViCentra | Series B | 10.9M |
| 4/2023 | Evommune | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 2/2022 | Perfuze | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
